BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

917 related articles for article (PubMed ID: 23806056)

  • 41. Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements.
    Sheu SY; Schwertheim S; Worm K; Grabellus F; Schmid KW
    Mod Pathol; 2007 Jul; 20(7):779-87. PubMed ID: 17464312
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma.
    Bansal M; Gandhi M; Ferris RL; Nikiforova MN; Yip L; Carty SE; Nikiforov YE
    Am J Surg Pathol; 2013 Oct; 37(10):1586-91. PubMed ID: 23797723
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas.
    Rodrigues R; Roque L; Espadinha C; Pinto A; Domingues R; Dinis J; Catarino A; Pereira T; Leite V
    Oncol Rep; 2007 Oct; 18(4):917-26. PubMed ID: 17786355
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetic alterations in thyroid tumors from patients irradiated in childhood for tinea capitis treatment.
    Boaventura P; Pereira D; Celestino R; Mendes A; Nakasawa T; Teixeira-Gomes J; Sobrinho-Simões M; Soares P
    Eur J Endocrinol; 2013 Nov; 169(5):673-9. PubMed ID: 23966419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the BRAF V600E Mutation: A Single-Institution Study.
    Kowalska A; Walczyk A; Kowalik A; Pałyga I; Trybek T; Kopczyński J; Kajor M; Chrapek M; Pięciak L; Chłopek M; Góźdź S; Kamiński G
    Thyroid; 2016 Apr; 26(4):543-51. PubMed ID: 26889698
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.
    Sadow PM; Heinrich MC; Corless CL; Fletcher JA; Nosé V
    Endocr Pathol; 2010 Jun; 21(2):73-9. PubMed ID: 20012784
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.
    Guerra A; Fugazzola L; Marotta V; Cirillo M; Rossi S; Cirello V; Forno I; Moccia T; Budillon A; Vitale M
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2333-40. PubMed ID: 22508706
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [
    Zhang X; Su X; Chen WC; Li Y; Yang ZY; Deng WZ; Deng TC; Yang AK
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jun; 52(6):435-439. PubMed ID: 28635216
    [No Abstract]   [Full Text] [Related]  

  • 49. Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings.
    Frau DV; Lai ML; Caria P; Dettori T; Coni P; Faa G; Morandi L; Tallini G; Vanni R
    J Clin Endocrinol Metab; 2008 Jan; 93(1):177-81. PubMed ID: 17956956
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Invasive properties of papillary thyroid cancer with concurrent BRAF(V600E) mutation and rearranged during transfection proto-oncogene protein expression].
    Meng C; Gao J; Liang J; Liang ZY; Lin YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Feb; 35(1):64-8. PubMed ID: 23469793
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.
    Liu RT; Chou FF; Wang CH; Lin CL; Chao FP; Chung JC; Huang CC; Wang PW; Cheng JT
    Thyroid; 2005 Apr; 15(4):326-35. PubMed ID: 15876154
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population.
    Gertz RJ; Nikiforov Y; Rehrauer W; McDaniel L; Lloyd RV
    Arch Pathol Lab Med; 2016 Feb; 140(2):134-9. PubMed ID: 26910217
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Significance of allelic percentage of BRAF c.1799T > A (V600E) mutation in papillary thyroid carcinoma.
    Cheng SP; Hsu YC; Liu CL; Liu TP; Chien MN; Wang TY; Lee JJ
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S619-26. PubMed ID: 24748129
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma.
    Salvatore G; Giannini R; Faviana P; Caleo A; Migliaccio I; Fagin JA; Nikiforov YE; Troncone G; Palombini L; Basolo F; Santoro M
    J Clin Endocrinol Metab; 2004 Oct; 89(10):5175-80. PubMed ID: 15472223
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BRAF overexpression is associated with BRAF V600E mutation in papillary thyroid carcinomas.
    da Silva RC; de Paula HS; Leal CB; Cunha BC; de Paula EC; Alencar RC; Meneghini AJ; Silva AM; Gontijo AP; Wastowski IJ; Saddi VA
    Genet Mol Res; 2015 May; 14(2):5065-75. PubMed ID: 26125698
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features.
    Durand S; Ferraro-Peyret C; Joufre M; Chave A; Borson-Chazot F; Selmi-Ruby S; Rousset B
    Endocr Relat Cancer; 2009 Jun; 16(2):467-81. PubMed ID: 19208736
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population.
    Brzeziańska E; Pastuszak-Lewandoska D; Wojciechowska K; Migdalska-Sek M; Cyniak-Magierska A; Nawrot E; Lewiński A
    Neuro Endocrinol Lett; 2007 Aug; 28(4):351-9. PubMed ID: 17693984
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The changing characteristics and molecular profiles of papillary thyroid carcinoma over time: a systematic review.
    Vuong HG; Altibi AM; Abdelhamid AH; Ngoc PU; Quan VD; Tantawi MY; Elfil M; Vu TL; Elgebaly A; Oishi N; Nakazawa T; Hirayama K; Katoh R; Huy NT; Kondo T
    Oncotarget; 2017 Feb; 8(6):10637-10649. PubMed ID: 27793009
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [BRAF initiating mutations in the papillary thyroid carcinoma].
    Rusinek D; Gubała E
    Endokrynol Pol; 2006; 57(4):438-44. PubMed ID: 17006850
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
    Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
    Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.